


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on September 7, 2006.



1645
IFW

INFORMATION DISCLOSURE
STATEMENT
Examining Group 1645
Patent Application
Docket No. G-194US04PCT
Serial No. 10/519,336


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645
Applicants : Daniel Cohen, Ilya Chumakov, Marta Blumenfeld, Sanober Shaikh, Marta Palicio-Barron, Hadi Abderrahim, Pascale Grel
Serial No. : 10/519,336
Filed : December 22, 2004
Conf. No. : 9315
For : Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether the copy of the reference cited in the International Search Report was received by the Patent Office. Therefore, a copy of the reference cited in the International Search Report is enclosed for the Examiner's convenience. In accordance with 37 CFR §1.56, Applicants hereby request that the reference cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants have also listed on form PTO/SB/08 numerous references which have not been cited in the International Search Report. Copies of these documents are enclosed with this IDS. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Art Unit	1645
Examiner Name	
Attorney Docket Number	G-194US04PCT

Sheet

1

of

5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 01/91026 A2	11-29-2001	Genset	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,336
				Filing Date	December 22, 2004
				First Named Inventor	Daniel Cohen
				Group Art Unit	1645
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	G-194US04PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGOSTINIS, P. <i>et al.</i> "A Comparative Study of the Phosphotyrosyl Phosphatase Specificity of Protein Phosphatase Type 2A and Phosphotyrosyl Phosphatase Type 1B using Phosphopeptides and the Phosphoproteins p50/HS1, c-Fgr and Lyn" <i>Eur. J. Biochem.</i> , 1996, pp. 548-557, Vol. 236.	
	R2	ALTSCHUL, S. F. <i>et al.</i> "Basic Local Alignment Search Tool" <i>J. Mol. Biol.</i> , 1990, pp. 403-410, Vol. 215.	
	R3	ALTSCHUL, S. F. <i>et al.</i> "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs" <i>Nucleic Acids Research</i> , 1997, pp. 3389-3402, Vol. 25, No. 17.	
	R4	ANDRIEUX, A. <i>et al.</i> "The Suppression of Brain Cold-Stable Microtubules in Mice Induces Synaptic Defects Associated with Neuroleptic-Sensitive Behavioral Disorders" <i>Genes and Development</i> , 2002, pp. 2350-2364, Vol. 16.	
	R5	BORRESEN, A-L. <i>et al.</i> "Detection of Base Mutations in Genomic DNA using Denaturing Gradient Gel Electrophoresis (DGGE) followed by Transfer and Hybridization with Gene-Specific Probes" <i>Mutation Research</i> , 1988, pp. 77-83, Vol. 202.	
	R6	DEMPSTER, A. P. <i>et al.</i> "Maximum Likelihood from Incomplete Data via the EM Algorithm" <i>JRSSB</i> , 1977, pp. 1-38, Vol. 39.	
	R7	DETERA-WADLEIGH, S. D. <i>et al.</i> "A High-Density Genome Scan Detects Evidence for a Bipolar-Disorder Susceptibility Locus on 13q32 and other Potential Loci on 1q32 and 18p11.2" <i>Proc. Natl. Acad. Sci. USA</i> , May 1999, pp. 5604-5609, Vol. 96.	
	R8	DEVEREUX, J. <i>et al.</i> "A Comprehensive Set of Sequence Analysis Programs for the VAX" <i>Nucleic Acids Research</i> , 1984, pp. 387-395, Vol. 12, No. 1.	
	R9	ELBASHIR, S. M. <i>et al.</i> "RNA Interference is Mediated by 21 and 22-Nucleotide RNAs" <i>Genes and Development</i> , 2001, pp. 188-200, Vol. 15.	
	R10	ELLINGTON, A. D. <i>et al.</i> "In vitro Selection of RNA Molecules that Bind Specific Ligands" <i>Nature</i> , August 30, 1990, pp. 818-822, Vol. 346.	
	R11	EXCOFFIER, L. <i>et al.</i> "Maximum-Likelihood Estimation of Molecular Haplotype Frequencies in a Diploid Population" <i>Mol. Biol. Evol.</i> , 1995, pp. 921-927, Vol. 12, No. 5.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,336
				Filing Date	December 22, 2004
				First Named Inventor	Daniel Cohen
				Group Art Unit	1645
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	G-194US04PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R12	GRANTHAM, R. "Amino Acid Difference Formula to Help Explain Protein Evolution" <i>Science</i> , September 6, 1974, pp. 862-864, Vol. 185.	
	R13	GROMPE, M. <i>et al.</i> "Scanning Detection of Mutations in Human Ornithine Transcarbamoylase by Chemical Mismatch Cleavage" <i>Proc. Natl. Acad. Sci. USA</i> , August 1989, pp. 5888-5892, Vol. 86.	
	R14	HU, P. <i>et al.</i> "Molecular Cloning and Mapping of the Brain-Abundant B1γ Subunit of Protein Phosphatase 2A, PPP2R2C, to Human Chromosome 4p16" <i>Genomics</i> , 2000, pp. 83-86, Vol. 67.	
	R15	JANSSENS, V. <i>et al.</i> "Protein Phosphatase 2A: A Highly Regulated Family of Serine/Threonine Phosphatases Implicated in Cell Growth and Signalling" <i>Biochem J.</i> , 2001, pp. 417-439, Vol. 353.	
	R16	KAELIN, W. G. <i>et al.</i> "Identification of Cellular Proteins That Can Interact Specifically with the T/E1A-Binding Region of the Retinoblastoma Gene Product" <i>Cell</i> , February 8, 1991, pp. 521-532, Vol. 64.	
	R17	KAELIN, W. G. <i>et al.</i> "Expression Cloning of a cDNA Encoding a Retinoblastoma-Binding Protein with E2F-Like Properties" <i>Cell</i> , July 24, 1992, pp. 351-364, Vol. 70.	
	R18	KAMIBAYASHI, C. <i>et al.</i> "Comparison of Heterotrimeric Protein Phosphatase 2A Containing Different B Subunits" <i>The Journal of Biological Chemistry</i> , August 5, 1994, pp. 20139-20148, Vol. 269, No. 31.	
	R19	KIM, S. <i>et al.</i> "Multiplex Genotyping of the Human β2-Adrenergic Receptor Gene using Solid-Phase Capturable Dideoxynucleotides and Mass Spectrometry" <i>Analytical Biochemistry</i> , 2003, pp. 251-258, Vol. 316.	
	R20	LESSA, E. P. <i>et al.</i> "Screening Techniques for Detecting Allelic Variation in DNA Sequences" <i>Molecular Ecology</i> , 1993, pp. 119-129, Vol. 2.	
	R21	NEWTON, C. R. <i>et al.</i> "Analysis of any Point Mutation in DNA. The Amplification Refractory Mutation System (ARMS)" <i>Nucleic Acids Research</i> , 1989, pp. 2503-2516, Vol. 17, No. 7.	
	R22	ORITA, M. <i>et al.</i> "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms" <i>Proc. Natl. Acad. Sci. USA</i> , April 1989, pp. 2766-2770, Vol. 86.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,336
				Filing Date	December 22, 2004
				First Named Inventor	Daniel Cohen
				Group Art Unit	1645
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	G-194US04PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R23	PAN, Z. <i>et al.</i> "Alternative Splicing of KCNQ2 Potassium Channel Transcripts Contributes to the Functional Diversity of M-Currents" <i>Journal of Physiology</i> , 2001, pp. 347-358, Vol. 531.2.	
	R24	PEARSON, W. R. "Rapid and Sensitive Sequence Comparison with FASTP and FASTA" <i>Methods in Enzymology</i> , 1990, pp. 63-98, Vol. 183.	
	R25	PEARSON, W. R. <i>et al.</i> "Improved Tools for Biological Sequence Comparison" <i>Proc. Natl. Acad. Sci. USA</i> , April 1988, pp. 2444-2448, Vol. 85.	
	R26	PRICE, N. E. <i>et al.</i> "Effects of Regulatory Subunits on the Kinetics of Protein Phosphatase 2A" <i>Biochemistry</i> , 2000, pp. 11312-11318, Vol. 39.	
	R27	RUANO, G. <i>et al.</i> "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules" <i>Proc. Natl. Acad. Sci. USA</i> , August 1990, pp. 6296-6300, Vol. 87.	
	R28	SARKAR, G. <i>et al.</i> "Haplotyping by Double PCR Amplification of Specific Alleles" <i>Biotechniques</i> , 1991, pp. 436-440, Vol. 10, No. 4.	
	R29	SCHWAKE, M. <i>et al.</i> "Surface Expression and Single Channel Properties of KCNQ2/KCNQ3, M-Type K ⁺ Channels Involved in Epilepsy" <i>Journal of Biological Chemistry</i> , May 5, 2000, pp. 13343-13348, Vol. 275, No. 18.	
	R30	SMITH, T. F. <i>et al.</i> "Comparison of Biosequences" <i>Advances in Applied Mathematics</i> , 1981, pp. 482-489, Vol. 2.	
	R31	STRACK, S. <i>et al.</i> "Brain Protein Phosphatase 2A: Developmental Regulation and Distinct Cellular and Subcellular Localization by B Subunits" <i>Journal of Comparative Neurology</i> , 1998, pp. 515-527, Vol. 392.	
	R32	TOWBIN, H. <i>et al.</i> "Electrophoretic Transfer of Proteins from Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and some applications" <i>Proc. Natl. Acad. Sci. USA</i> , September 1979, pp. 4350-4354, Vol. 76, No. 9.	
	R33	USUI, H. <i>et al.</i> "Three Distinct Forms of Type 2A Protein Phosphatase in Human Erythrocyte Cytosol" <i>Journal of Biological Chemistry</i> , March 15, 1988, pp. 3752-3761, Vol. 263, No. 8.	
	R34	WEN, S-Y. <i>et al.</i> "Rapid Detection of the Known SNPs of CYP2C9 using Oligonucleotide Microarray" <i>World J. Gastroenterol.</i> , 2003, pp. 1342-1346, Vol. 9, No. 6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,336
				Filing Date	December 22, 2004
				First Named Inventor	Daniel Cohen
				Group Art Unit	1645
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	G-194US04PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R35	WU, D. Y. <i>et al.</i> "Allele-Specific Enzymatic Amplification of β -Globin Genomic DNA for Diagnosis of Sickle Cell Anemia" <i>Proc. Natl. Acad. Sci. USA</i> , April 1989, pp. 2757-2760, Vol. 86.	
	R36	ZOLNIEROWICZ, S. <i>et al.</i> "Diversity in the Regulatory B-Subunits of Protein Phosphatase 2A: Identification of a Novel Isoform Highly Expressed in Brain" <i>Biochemistry</i> , 1994, pp. 11858-11867, Vol. 33, No. 39.	
	R37	SwissProt Accession No. Q9Y2T4.	
	R38	SwissProt Accession No. O43526.	
	R39	Genbank Accession No. AF086924.	
	R40	Genbank Accession No. AF033348.	
	R41	RefseqN Accession No. NT_006051.	
	R42	EMBL Accession No. AC114815.5.	
	R43	EMBL Accession No. AC004599.6.	
	R44	EMBL Accession No. AC122939.3.	
	R45	EMBL Accession No. AC004689.5.	
	R46		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.